Sign in

CIK 0001953926

  • Emerging growth company

Zenas BioPharma, Inc.

Sign in to watch
Ticker
ZBIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 857-271-2954
Business address
852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
Former names
Zenas BioPharma (Cayman) Ltd
  1. 4 Derivatives Options or other derivatives
  2. 4/A Open-market buy Director bought 10,000 shares at $7.76 ($77,600)
  3. 4 Derivatives Options or other derivatives
  4. 3 Insider Initial Statement of Ownership
  5. 4 Open-market buy Chief Executive Officer bought 25,000 shares at $6.67 ($166,750)
  6. 4 Open-market buy Director bought 10,000 shares at $7.76 ($77,600)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Open-market buy Chief Executive Officer bought 70,000 shares at an average $10.26 ($718,100)
  10. 4 Open-market buy Chief Executive Officer bought 10,000 shares at an average $14.89 ($148,925)
  11. 4 Open-market buy Chief Executive Officer bought 20,000 shares at an average $18.04 ($360,820)
  12. 4 Conversion 10% owner acquired 801,624 shares (conversion)
  13. 4 Open-market buy 10% owner bought 882,353 shares at $17.00 ($15,000,001)
  14. 4/A Open-market buy Director bought 300,000 shares at $17.00 ($5,100,000)
  15. 4/A Conversion Chief Executive Officer acquired 693,175 shares (conversion)
  16. 4 Open-market buy Director bought 58,823 shares at $17.00 ($999,991)
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 3 of 5 · 84 filings